Menu Menu

News

Featured
COVID-19 Research Pipeline

144,298

Registered/ Published

4,334

Registered

672

Published

6,177

Registered
As at 24 June 2022
FILTERED BY > Sotrovimab Clear filter

Communique #65

9 May, 2022
Click for the latest Taskforce news:
Communique

Communique #64

8 April, 2022
Click the latest Taskforce news: 
Communique

Communique #62

31 March, 2022
Click for the latest Taskforce news:   
Communique

Taskforce updates Sotrovimab remark (v54.0)

28 March, 2022
The Taskforce has updated the remarks on its sotrovimab 'for use' recommendations to include: The Taskforce is aware of in vitro data suggesting a potential reduction in efficacy...
News

I’ve tested positive for COVID-19? What treatments are available?

9 March, 2022
  With several new drug treatments for people with mild COVID-19 now available, it can be tricky to know what your options are should you test positive to...
Explainer

Communique #57

3 February, 2022
Click for the latest Taskforce news:
Communique

Communique #52

29 October, 2021
Click for the latest Taskforce news:
Communique

Communique #50

29 September, 2021
WEEK IN REVIEW Updates to the Living Treatment Guideline New recommendations Seven new treatment recommendations for pregnant and breastfeeding women Sotrovimab for pregnant women Following recent recommendations for the...
Communique

Communique #49

26 August, 2021
WEEK IN REVIEW Taskforce makes new conditional recommendation for sotrovimab The Taskforce today published three recommendations on the use of sotrovimab for the treatment of COVID-19 in adults...
Communique

Taskforce makes conditional recommendation for use of sotrovimab 

26 August, 2021
The National COVID-19 Clinical Evidence Taskforce today published three recommendations on the use of sotrovimab for the treatment of COVID-19 in adults who do not require oxygen and...
Media Release

Communique #47

1 July, 2021
WEEK IN REVIEW Updates to the Living Treatment Guideline New recommendations Three new recommendations for the use of Casirivimab plus imdevimab (REGEN-COV) The Disease-Modifying Treatment and Chemoprophylaxis Panel...
Communique